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Abstract
Background: A patient- and surgeon-Delphi-derived Outcome Measures in Rheumatology (OMERACT) draft core
domain set for total joint arthroplasty (TJR) trials was recently developed. Our objective was to obtain further
patient stakeholder endorsement of draft core domain set for TJR clinical trials.
Methods: We surveyed two patient groups: (1) OMERACT patient partners; and (2) patients who had undergone
hip or knee TJR. Patients received an introductory email with explanations about the core domain set and
instructions to rate the core domains, i.e., important aspects, of OMERACT TJR clinical trial draft core domain set.
Rating was on a nominal scale, where 1–3 indicated a domain of limited importance, 4–6 an important, but not
critical domain, and 7–9 a critical domain. We used Mann–Whitney test (a non-parametric test) to compare the
distribution of ratings between the two groups.
Results: Thirty one survey participants from the OMERACT patient partner group and 118 knee/hip TJR patients
responded with response rates of 66 and 80%, respectively. Majority of the survey respondents were female, 87 vs.
53%, and were 55 years or older, 57 vs. 94%. Median (interquartile range [IQR]) scores for six core domains by
OMERACT and knee/hip TJR patient groups were, respectively: pain, 8 [8, 9] and 9 [8, 9]; function, 9 [8, 9] and 9 [8,
9]; patient satisfaction, 8 [8, 9] and 8 [7, 9]; revision surgery, 7 [7, 8] and 7 [5, 9]; adverse events, 8 [7, 9] and 8 [6, 9];
and death, 9 [6, 9] and 9 [4, 9]. No statistically significant differences in rating were noted for any of the six core
domains between the two groups (p ≥ 0.31). Among the additional domains, ratings for patient participation did
not differ by group (p = 0.98), but ratings for cost were significantly different (p = 0.005). Patients provided
qualitative feedback regarding core domains, and did not propose any modifications to the draft core domain set.
Conclusions: Two separate patient stakeholder groups endorsed the OMERACT TJR draft core domain set for TJR trials.
Background
Total Joint Replacement (TJR) is a very successful and cost
effective surgical treatment for refractory end-stage arthritis
in patients who report pain and/or functional limitation.
Majority of the patients report impressive improvements in
pain and function with this surgery [1, 2], while a small pro-
portion have an unsatisfactory outcome from TJR [3, 4],
including persistent pain and functional limitation [5–10].
Although hip and knee TJR are the most common joints re-
placed currently, we realize that TJR for other joints is also
becoming more common in the recent years [11–15]. While
the rapid advances in implant design and surgical tech-
niques have occurred for TJR, TJR trial reporting has not
kept pace with this quick evolution. Development of valid
outcome measures, universal adoption and harmonization
continues to be a big challenge. As a result, patients and
surgeons have not been able to effectively capitalize on the
large and growing body of data for cross study comparisons.
Moreover, the heterogeneity in outcome measures used in
TJR trials [16] prevents meta-analysis and literature
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synthesis and this is compounded by the limited validity
of several of the outcome instruments being used [17]. Re-
cent studies confirmed that these challenges continue in
knee TJR trials [18, 19]. In 2006, our group recognized the
need for consensus and harmonization of reporting of TJR
trials [20]. We have built capacity and capability by under-
taking several systematic reviews and building collabora-
tions, which have continued over the last decade. This has
led to the formation of an international Working group
(WG) on TJR clinical trial outcomes that is now an
orthopedist-patient-rheumatologist-methodologist multi-
stakeholder collaborative [21].
Using the Outcomes Measures in Rheumatology
(OMERACT) filter for developing core measurement sets,
we developed a multi-stakeholder endorsed TJR trial draft
core domain set, based on systematic literature reviews,
followed by input from patients and surgeons using a Del-
phi process [21] and mailed surveys. The OMERACT TJR
draft core domain set (for any joint) included the following:
Pain, function, patient satisfaction, revision, adverse events,
and death [21]. The OMERACT TJR trial draft core do-
main set was developed based on systematic literature re-
views, several multi-stakeholder discussions at OMERACT
and various orthopedic meetings that included leaders in
arthroplasty registries, trials and outcome science, Delphi
surveys and a face-to-face discussion of each potential core
domains with patients, orthopedic surgeons, methodologist,
physical and occupational therapists and rheumatologists,
details provided elsewhere [21]. This outcome draft core
domain set is consistent with previous systematic reviews
of patient outcomes after TJR and qualitative studies of
patient perspective of TJR outcomes [3, 16, 22–24]. In a
subsequent consensus-building exercise, we achieved a
complete consensus for this draft TJR core domain set with
two independent groups of orthopaedic surgeons, who
endorsed all six core domains [25].
As part of our long-term objective to develop and
implement a TJR core measurement set, the aim of the
current study was to obtain further endorsement of the
OMERACT TJR trial draft core domain set, for any TJR
for any joint, as defined previously [21]. We aimed to
survey new patient groups, who are representative inter-
nationally, and are independent of the patient group that
helped us develop the original draft core domain set.
Another objective was to identify whether these inde-
pendent patient surveys find evidence for modifying our
preliminary OMERACT TJR trial core. This study
describes the process of obtaining further endorsement
of the OMERACT TJR trial draft core domain set for
any joint from a wider patient audience.
Methods
We surveyed two groups of patients. The first group in-
cluded the OMERACT patient research partner (PRPs),
a group of patients with rheumatic diseases (predomin-
antly arthritis, but also including patients with immune
conditions) who had attended one of the biannual
OMERACT meetings including the 2016 OMERACT
meeting at Whistler, Canada (n = 47). The second group
was a cohort of patients who had undergone hip or knee
replacement at St. Vincent’s Private Hospital (SVPH),
Melbourne, Australia between January 2013 and Decem-
ber 2014 (n = 147). This cohort was identified through
the St. Vincent’s Melbourne Arthroplasty Registry
(SMART), approved by the Human ethics committee at
St. Vincent’s Hospital, Australia (HREC-A 100/14; there
is no published protocol). We recruited patients after
knee or hip TJR, since our goal was to develop a core
domain set for TJR trials, and therefore recruiting pre-
operative patients does not address our main question.
We developed and pre-tested a survey questionnaire,
which was reviewed by several colleagues with previous
TJR attending the OMERACT meeting, study team
members as well as patients in the SMART registry.
Subsequently, it was iteratively modified, based on the
feedback, including clarification of the questions and
simplification of the cover letter, the background and the
purpose of the questionnaire. The survey queried patient
characteristics and the importance of each domain of
the OMERACT TJR trial draft core domain set, includ-
ing the six core areas/domains (pain, function [ability to
function in society, work; work productivity, employabil-
ity; disability; work disability], patient satisfaction [satis-
faction with the outcome, satisfaction with the
procedure], revision surgery, adverse event and death)
and two optional areas/domains (patient participation in
life/social activities, cost).
Patients rated each core domain on a 1–9 scale, devel-
oped by the GRADE group, used by us for rating out-
comes in previous studies of development of treatment
guideline [26, 27] and our previous studies ranking disease
core domains [25, 28]: 1–3 indicated a domain of limited
importance, 4–6 an important, but not critical domain,
and 7–9 a critically important domain. Surveys were
emailed to both groups of patients. In addition, a hard
copy was mailed to patients from the SVPH cohort with-
out email addresses (n = 23). Patients completed these
annonymized surveys using Survey Monkey link sent to
their emails or a mailed copy. Those not responding
received two reminders at least 1-week apart.
We defined the purpose of patient surveys in our pre-
vious paper, which was to assess whether patients could
achieve consensus on the current core domain set for
TJR trials, seek patient endorsement of the core domain
set and in case of any suggestions for modification/s, the
reasons for change in core domains [21]. We defined the
consensus as follows. If both groups of patients would
rate each core domain between 7–9, i.e., critical, this
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would constitute complete consensus. If both patient
groups rated a majority of the six core domains, but
not all, as critical, we would consider this as incomplete
consensus. In case of incomplete consensus, we would
have further discussion with patients and we would
plan to modify the draft TJR trial core domain set for
any joint. If the patient groups achieved complete con-
sensus on core domains, given the previous complete
consensus by orthopaedic surgeons [25], the draft TJR
core domain set would be considered endorsed by both
patients and orthopaedic surgeons at this stage. We cal-
culated summary statistics including proportions and
medians (interquartile range), as applicable, separately
for the OMERACT PRP and the SVPH patient cohorts.
We used a non-parametric test, Mann–Whitney to
compare the distribution of ratings between the two
groups and considered a p-value <0.05 to be statistically
significant.
Results
Survey response rates were good to excellent, 66% for
OMERACT PRPs and 80%, for SVPH patients. The two co-
horts differed in gender, age and diagnosis (Table 1). Com-
pared to the SVPH cohort, OMERACT PRP group had
greater proportions of females, 87 vs. 53%, those with a
diagnosis of RA, 4 vs. 54%, and was younger (Table 1). 85%
of OMERACT and 97% of SVPH patients had a diagnosis
of arthritis. A key difference was that 27% of OMERACT
and 100% of the SVPH cohort had had a joint replacement.
Despite these differences, both cohorts rated OMER-
ACT TJR clinical trials core domains similarly (Table 2).
On a 1 to 9 scale, all six-core domains were rated as crit-
ical domains (score 7–9); the additional domains of cost
and participation were scored important to critical (scores
6–8) (Table 2). None of the core domain set ratings dif-
fered significantly between the two groups (Table 2). For
additional domains, participation ratings were not statisti-
cally significantly different by group but rating for cost as
an additional domain was statistically significantly higher
for the SVPH Cohort compared to the OMERACT
patient cohort (p = 0.005; Table 2).
We received additional free text comments, which
provided insight into defining these core domains fur-
ther and suggestions as to which instruments we should
consider for the next step in the development of the TJR
clinical trial core measurement set (Additional file 1).
Additional areas brought up for consideration included
several that are either included as core domain or are
closely related to it: [1] life of an implant (same as
the core domain, revision); [2] Recovery and rehabili-
tation (similar to pain, function or functional ability,
satisfaction); [3] Independence (similar to function or
functional ability).
Discussion
This study describes patient consensus and endorsement
of the OMERACT TJR trial draft core domain set, which
was first developed and endorsed with multi-stakeholder
input in 2014, including patients and surgeons, after
completing several systematic reviews that helped iden-
tify potential core domain set [21]. As described in our
previous study, the current study completes step 5, i.e.,
patient endorsement of the preliminary OMERACT TJR
trial core domain set, such that we now have an OMER-
ACT TJR trial draft core domain set. We specified a
priori that patients and surgeons were our two key
stakeholders [21]. Therefore, the completion of this pa-
tient survey that followed surgeon survey [25], which
was published in the interim, provided us with consen-
sus we were aiming for TJR trial core domain set. Both
surgeons and patients have achieved consensus on TJR
trial core domain set consisting of six core domains,
and no modification is needed, based on the results
of these two studies. Several findings in this study
merit further discussion.
Table 1 Participant characteristics of the two patient cohorts
OMERACT Patient
research partner (PRP)




# Survey participants N = 31 (66%) N = 118a (80%)
% Maleb 4 (13%) 50 (47%)
Age categoryb
18-24 0 0
25-34 1 (3%) 0
35-44 3 (10%) 1 (1%)
45-54 9 (30%) 5 (5%)
55-64 11 (37%) 26 (25%)
65-74 6 (20%) 36 (34%)
≥75 0 37 (35%)
Missing 2 (7%) 2
Had a joint
replacement
13 (42%) 107 (100%)
Type of arthritis
Osteoarthritis 2 (7%) 93 (87%)
Rheumatoid arthritis 15 (54%) 4 (4%)
Other inflammatory
arthritis
7 (26%) 7 (6%)
Joint aches/pains,
no arthritis
diagnosed or no joint
aches/pains
4 (15%) 3 (3%)
aOf the 147 patients who received the survey (email, n = 124; mailed survey,
n = 23), 118 responded (email, n = 109; mailed survey, n = 9), of which 107
were usable (email, n = 99; mailed survey, n = 9). Therefore, most proportions
are out of 107 (73% valid surveys)
bMissing responses for variables for OMERACT PRPs vs. TJR SVPH cohorts: sex:
0 vs. 2; age, 0 vs. 2
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A key aspect of core domain development is its en-
dorsement by a wider group of stakeholders. The
OMERACT process uses cutting-edge methodological
science and rigor and is a data-driven and consensus-
based development of outcome instruments for clinical
trials. The OMERACT filter 2.0 provides a well-
described framework for the development of core do-
main and core measurement sets [29]. Although this
process of developing a multi-stakeholder group and de-
veloping the core domain set has taken a long time since
we started a decade ago, we have followed the OMER-
ACT methodology rigorously [21]. We believe that this
rigor will ultimately help with a wider acceptance and
uptake of the TJR trial core domain set. We have now
developed core domain set for TJR trials based on the
OMERACT filter 2.0 [29, 30].
Our current study shows that two groups of patients
endorsed the OMERACT TJR trial preliminary core do-
main set, rating all six domains as critical. Despite differ-
ences in patient characteristics, the ratings by two
cohorts were similar, which is a testament to a rigorous
process that we have used to develop this draft core do-
main set. This draft TJR trial core domain set has now
been endorsed by several independent groups of patients
and orthopaedic surgeons, two key stakeholders.
The methodology for core domain set development for
TJR trials was a standard method of defining every do-
main that is core to the condition, i.e., there is no
prioritization [29–31]. Therefore, the patient survey elic-
ited responses whether each of the core/additional do-
mains was core to TJR outcome or not at its own merit,
without asking them to prioritize the domains. The last
two steps in this process are dissemination and a wider
endorsement of the core domain set by orthopedic
surgeons, and the development, validation and endorse-
ment of a TJR trial core measurement set by a multi-
stakeholder group, and possible co-branding of this
OMERACT TJR trial draft core domain set and core
measurement set by interested orthopedic societies.
This study shows that a few patients identified add-
itional potential domains, including recovery and rehabili-
tation. It may be debated whether these are already
represented by the core domains currently included i.e.
pain, function or functional ability and patient satisfaction.
The definitions for function [ability to function in society,
work; work productivity, employability; disability; work
disability] and satisfaction [[satisfaction with the outcome,
satisfaction with the procedure] and domain of pain indi-
cated to us that recovery and rehabilitation are processes
that are intertwined with these core domains and perhaps
already captured to some extent with these domains.
However, in order to ensure appropriate rigor and inclu-
siveness, further discussions are required with wide stake-
holder input, regarding whether these should be optional
domains or be on research agenda.
We noted that real-world concerns were also brought
up by a few participants related to TJR that are not rele-
vant for TJR clinical trial reporting. Examples include ac-
cess to and wait times for TJR, which are related to
health care access and are country and setting-specific
contextual factors, likely relevant for observational stud-
ies and/or public policy discussions. These are important
policy concerns, but not relevant to TJR clinical trial
core domain selection.
Our study has several limitations. Survey response
rates were 66 and 80%, but we do not have non-re-
sponder characteristics to understand how non-response
influenced our findings. However, the high response rate









Core Domains to be reported in every TJR clinical trial
Joint Pain 8 [8, 9] 9 [8, 9] 0.75
Function or functional ability
(ability to function in society, work; work productivity, employability;
disability; work disability)
9 [8, 9] 9 [8, 9] 0.31
Patient Satisfaction
(satisfaction with the outcome, satisfaction with the procedure)
8 [8, 9] 8 [7, 9] 0.86
Revision surgery (including reoperation) 7 [7, 8] 7 [5, 9] 0.97
Adverse events (total and specific) 8 [7, 9] 8 [6, 9] 0.84
Death 9 [6, 9] 9 [4, 9] 0.70
Additional domains for consideration for reporting in TJR clinical trials
Patient Participation 8 [6.5, 8] 7 [6, 9] 0.98
Cost 6 [5, 7] 7 [6, 8] 0.005
a118 responded, of which 107 had valid, analyzable responses
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should give readers more confidence in these findings.
To strengthen our conclusions, we attempted to get a
wide perspective by polling representative groups, in-
cluding patients who had undergone knee/hip TJR. We
surveyed only adults and focused on knee or hip TJR tri-
als. These findings cannot be generalized to TJR that in-
volve other joints. Study strengths included the
assessment of the validity of core domain sets in two pa-
tient populations, an international representativeness of
sample, robustness of findings despite patient character-
istic differences in survey participants, and a high re-
sponse rate.
Conclusions
In conclusion, two patient groups in separate surveys
have now endorsed the OMERACT TJR trial draft core
domain set. The OMERACT TJR draft core domain set
was previously developed with multi-stakeholder input,
including patients and surgeons. All current core and
additional domains were endorsed as they are, without
any modification. With a parallel consensus from ortho-
paedic surgeons showing consensus for the 6 domains
(In a different study of the same core domains), both pa-
tients have achieved consensus on TJR trial draft core
domain set consisting of six core domains, and based on
the results of these two studies, no modification is
needed. We also obtained important feedback regarding
these domains, which will be instrumental in our next
steps of instrument selection for each of the core do-
mains. The planning is currently underway to seek a
wider dissemination to and/or endorsement by general
membership of arthroplasty surgeon societies and/or
OMERACT. If the draft core domain set is also en-
dorsed by a wider orthopedic society membership, we
will proceed with the development of first consensus-
based data-driven TJR trial core measurement set.
Additional file
Additional file 1: Additional Comments from Delphi Process. This file
provides the free text comments from both the OMERACT group as well
as the St. Vincent's Hospital Cohort regarding the core domains and
other suggested domains. (DOCX 127 kb)
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